KRAS変異は,ZNF24/SLC7A5/PD-L1軸経由で肺腺がんの免疫脱出を促進する
Leilei Li1,2, Qiang Feng2, Ya Jiang2
1Graduate School, Kunming Medical University, Kunming, Yunnan, 650500, People's Republic of China.
BMC cancer
|September 2, 2025
まとめ
KRAS変異はZNF24/SLC7A5/PD-L1経路経由で肺腺がんの免疫脱出を促す. ZNF24をダプトマイシンとPD- L1阻害で標的化すると,これらの患者の抗腫瘍免疫が強化される可能性があります.
科学分野:
- 腫瘍学
- 免疫学
- 分子生物学
背景:
- 免疫チェックポイントの分子の不均衡は 腫瘍の免疫回避を容易にする
- KRAS変異は,肺腺がんにおけるPD- L1発現のレギュレータとして知られています.
- KRAS変異とPD-L1の調節を結びつける正確なメカニズムについては,さらなる解明が必要である.
研究 の 目的:
- KRAS変異が肺腺がんにおけるPD- L1発現を調節するメカニズムを調査する.
- この過程におけるZNF24/SLC7A5軸の役割を探求する.
- この経路を標的とした治療戦略を評価し,抗腫瘍免疫を強化する.
主な方法:
- KRAS変異,ZNF24,SLC7A5,および肺腺癌組織および細胞系におけるPD- L1発現の分析
- ZNF24/SLC7A5/PD-L1軸によるCD8+T細胞免疫に対するKRAS変異の影響を評価するインビトロおよびインビボ実験.
- 抗腫瘍免疫に対するZNF24阻害とPD- L1阻害の効果の評価
主要な成果:
- KRAS変異は,ZNF24/ SLC7A5軸経由でPD- L1発現を調節し,肺腺がんにおけるCD8+ T細胞活性化を抑制する.
- ダプトミシン (DAPT) は,ZNF24を結合し,無効化する最初のZNF24阻害剤として特定されました.
- DAPTと抗PD- L1抗体の併用療法により,CD8+T細胞媒介の抗腫瘍免疫が強化される可能性がある.
結論:
- KRAS変異はZNF24/SLC7A5/PD-L1軸を通って肺腺がんの免疫脱出を促進する.
- この研究では,ZNF24がKRAS主導のPD- L1発現の主要な媒介体であると特定されています.
- ZNF24/SLC7A5/PD-L1軸を標的とした治療は,KRAS変異性肺腺癌の有望な治療戦略です.
さらに関連する動画
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
541
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.5K
関連する概念動画
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Cancer Cell Migration through Invadopodia
2.4K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.4K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
